681249-56-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE is used as a building block for the synthesis of new drugs, leveraging its unique structure to create compounds with novel therapeutic properties. Its potential applications in this industry include the development of treatments for various diseases and conditions, given its capacity to be incorporated into a wide range of molecular frameworks.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE is utilized as a component in the creation of new crop protection products. Its incorporation into these products can enhance their effectiveness in protecting crops from pests and diseases, thereby contributing to increased agricultural productivity and food security.
Used in Research and Development:
2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE serves as a valuable scaffold in the research and development of new chemical entities with biological activity. Its unique structural features make it an attractive candidate for the exploration of new molecular interactions and the discovery of compounds with potential applications in various fields, including medicine, agriculture, and materials science.

Upstream product

• 681249-55-8 C₆H₅F₃N₄O 
• 681249-55-8 2,2,2-trifluoro-N’-hydroxy-N-pyrazin-2-ylacetimidamide 

Downstream Products

• 681249-57-0 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine 

Relevant academic research and scientific papers

Synthesis process of PARP inhibitor fluzopanb intermediate

The invention discloses a process method suitable for large-scale preparation of 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine, and belongs to the field of drug intermediate synthesis, wherein 2-aminopyrazine and ethyl trifluoroacetate are used as raw materials, and a transesterification reaction, a substitution reaction and a dehydration reaction are performed to obtain 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine. According to the process disclosed by the invention, cheap ethyl trifluoroacetate is selected to replace expensive trifluoroacetic anhydride, other organic solvents replace a first-class solvent dichloroethane, and TFFA replaces PPA which is difficult to post-treat, so that the production cost of existing biological, medical and chemical intermediates is greatly reduced, amplification verification is conducted on the kilogram-level scale of the process, the yield and the product purity are basically equivalent to those of the gram-level scale, and the process is expected to serve as an industrial large-scale production process.

Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

Various β-amino amides containing triazolopiperazine heterocycles have been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. These compounds display excellent oral bioavailability and good overall phar

AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.